RESEARCH

The VISION Vaccine Effectiveness Network is a research collaboration between CDC, Westat, and multiple sites with integrated clinical, laboratory, and vaccination records in the United States that evaluate how well seasonal influenza (flu) vaccines protect people against flu, RSV vaccines protect people against RSV, and COVID-19 vaccines protect against COVID-19. VISION also assesses information on severe outcomes among people hospitalized with laboratory-confirmed flu and COVID-19 including intensive care unit (ICU) admission, invasive mechanical ventilation, and in-hospital death. These data help inform how well flu vaccines, RSV vaccines, and COVID-19 vaccines protect against severe outcomes.

The major goal of this project is to characterize and estimate the probability of antibiotic resistance among adult patients with complicated urinary tract infections (cUTIs) in the outpatient setting, as well as characterize cUTI patients who are at risk for treatment failure.

The objectives of this large retrospective data-only study are to use two parallel study designs to assess the VE of Pfizer COVID-19 vaccine against 2 primary endpoints: 1.) Severe outcomes (COVID-19 associated hospitalization, ICU admission, and death); and 2.) Outpatient laboratory-confirmed COVID-19 diagnosis.

Respiratory Syncytial Virus (RSV) is a major cause of respiratory infection for infants and older adults. In this study, we will estimate vaccine effectiveness of Pfizer’s RSVpreF vaccine against RSV-related lower respiratory tract infection requiring hospitalization among KPSC older adults who are eligible for vaccination per current ACIP recommendations.

The purpose of this study is to provide critical information about the predictors of severe RSV disease, describe epidemiology and burden of hospitalized RSV disease in older adults, and assess healthcare utilization associated with hospitalized RSV disease in older adults in a community setting. A population of hospitalized older adults testing positive for influenza will also be identified for comparison purposes.

This is a real-world study evaluating the effectiveness of mRNA-1083 (Moderna’s influenza and COVID-19 combination vaccine) in preventing seasonal Influenza and COVID-19 hospitalizations among adults 50 years and older. The Moderna protocol number is mRNA-1083-P904.

This observational study aims to assess the vaccine effectiveness of Arexvy in preventing laboratory-confirmed RSV-acute respiratory infection (ARI)/LRTD hospitalization in adults>=60 years at Kaiser Permanente Southern California, using a test-negative design.

The overall goal of this feasibility work will be to develop a protocol for the main outpatient C. difficile study that will achieve the goals of the retrospective, prospective, and validation components outlined by the funder.

Comparative vaccine effectiveness of influenza vaccine in the 2022-2023 season.

This study compares healthcare utilization and costs attributable to hospitalizations for human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) infections for adults aged =18 years between 2011 and 2024.

RSV is a major cause of respiratory infection in both infants and older adults, and clinical manifestations can be severe. This study will evaluate the vaccine effectiveness of Pfizer’s ABRYSVO vaccine against RSV-related lower respiratory tract infection requiring hospitalization among Kaiser Permanente Southern California members ages 60 and older who are eligible for vaccination per current ACIP recommendations.

Elevated tissue and serum levels of IL-6 have been implicated in the disease pathology of several inflammatory and autoimmune disorders including rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA), and cytokine-release syndrome (CRS). Tocilizumab or TCZ (Actemra) is a recombinant humanized, anti-human monoclonal antibody directed against soluble and membrane-bound IL-6R. On March 3rd 2020, TCZ was included in the updated diagnosis and treatment plan for COVID-19 issued by the China National Health Commission as one treatment option for severe or critical forms of COVID-19 pneumonia. However, despite fairly widespread use in China, Actemra has not received health authority approval for COVID-19 in any country. More robust clinical evidence regarding the safety or efficacy of TCZ in the treatment of COVID-19 is needed. Roche is conducting a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of TCZ in combination with SOC compared with matching placebo in combination with SOC in hospitalized adult patients with severe COVID-19 pneumonia (n=330). KPSC is collecting demographic, comorbidity, and clinical information on KPSC patients hospitalized with COVID-19 infection to create a real world data (RWD) comparator arm that will be matched to the TCZ treatment arm of the RCT.